IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival
| Autor: | S. Danese, S. Fracchioli, Marco Massobrio, He Yu, M J Khosravi, Dionyssios Katsaros, F. Genta, A. Diamandi, Michael A. Levesque, G. Richiardi, Eleftherios P. Diamandis, G Gordini |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Pathology medicine.medical_treatment Enzyme-Linked Immunosorbent Assay Ovary Disease Disease-Free Survival Risk Factors Internal medicine Biomarkers Tumor medicine Carcinoma Humans Neoplasms Glandular and Epithelial Risk factor Pathological Aged Neoplasm Staging Aged 80 and over Ovarian Neoplasms Chemotherapy business.industry Middle Aged Prognosis medicine.disease Neoplasm Proteins Insulin-Like Growth Factor Binding Protein 3 medicine.anatomical_structure Tumor progression Female business Ovarian cancer Follow-Up Studies |
| Zdroj: | European Journal of Cancer. 37:478-485 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/s0959-8049(00)00423-8 |
| Popis: | Insulin-like growth factor binding protein-3 (IGFBP-3) regulates the mitogenic and anti-apoptotic actions of insulin-like growth factors (IGFs). To study the role of IGFBP-3 in ovarian cancer progression, we measured IGFBP-3 concentrations in tumour tissues from 147 patients with epithelial ovarian carcinoma and examined its associations with clinicopathological features of disease and patient survival. The average age of the patients was 54.6 years (range 25-88 years) and the median follow-up time was 37 months. IGFBP-3 levels were measured with a commercial immunoassay kit. Low IGFBP-3 levels were significantly associated with unfavourable prognostic features of the disease, including advanced stage (P=0.048), large size of residual tumour (P=0.007), and suboptimal debulking outcome (P=0.007). Low IGFBP-3 levels were also associated with a significantly increased risk for disease progression (RR=1.92; 95% confidence interval (CI) 1.05-3.45; P=0.034), but the association was not sustained when other clinical and pathological variables were adjusted for in the analysis. No significant associations were observed between the IGFBP-3 level and patients' overall survival and response to chemotherapy. Findings of the study indicate that IGFBP-3 may play a role in the progression of epithelial ovarian cancer, but that it has no independent value in predicting either disease prognosis or the response of patients to chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect